

# Christopher Wai Kei Lam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9093336/publications.pdf>

Version: 2024-02-01

43  
papers

1,290  
citations

361413

20  
h-index

361022

35  
g-index

43  
all docs

43  
docs citations

43  
times ranked

2275  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 29-42.  | 1.8 | 4         |
| 2  | The role of sulfonylureas in the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 387-403.  | 1.8 | 14        |
| 3  | An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, , 1-9.  | 3.3 | 7         |
| 4  | Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T &gt; C Polymorphism. <i>Frontiers in Nutrition</i> , 2022, 9, .  | 3.7 | 1         |
| 5  | The beneficial effects of <i>Ganoderma lucidum</i> on cardiovascular and metabolic disease risk. <i>Pharmaceutical Biology</i> , 2021, 59, 1159-1169.   | 2.9 | 16        |
| 6  | Personalized medicine in lipid-modifying therapy. <i>Personalized Medicine</i> , 2021, 18, 185-203.   | 1.5 | 2         |
| 7  | Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia. <i>Endocrinology and Metabolism</i> , 2021, 36, 279-295.   | 3.0 | 16        |
| 8  | Managing dyslipidemia in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2221-2234.   | 1.8 | 14        |
| 9  | Is There Still a Role for Sulfonylureas in Type 2 Diabetes?. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2021, 18, .  | 0.2 | 0         |
| 10 | Statin Controversies Continued: Response to the Letter from Azemawah et al.. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 887-888.   | 2.6 | 0         |
| 11 | Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2137-2151.  | 1.8 | 7         |
| 12 | Statin Pharmacology Revisited. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 225-226.   | 2.6 | 0         |
| 13 | Pharmacokinetics of current and emerging treatments for hypercholesterolemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 371-385.  | 3.3 | 9         |
| 14 | Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 147-157.  | 2.4 | 12        |
| 15 | Consumption of Sugar-Sweetened Beverages Has a Dose-Dependent Effect on the Risk of Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Dose-Response Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2192. | 2.6 | 67        |
| 16 | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM±) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.  | 6.8 | 104       |
| 17 | A case of simvastatin-induced myopathy with <i>SLCO1B1</i> genetic predisposition and co-ingestion of linagliptin and <i>Stevia rebaudiana</i> . <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 381-383.  | 1.5 | 9         |
| 18 | Anti-Inflammatory Activities of Pentaherbs formula and Its Influence on Gut Microbiota in Allergic Asthma. <i>Molecules</i> , 2018, 23, 2776.   | 3.8 | 31        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Statin Responses in Chinese Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 199-202.   | 2.0 | 24        |
| 20 | Alirocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 633-643.  | 3.1 | 23        |
| 21 | Evolocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.   | 3.1 | 5         |
| 22 | Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 211-223.                    | 3.3 | 16        |
| 23 | Clinical Signs, Staphylococcus and Atopic Eczema-Related Seromarkers. <i>Molecules</i> , 2017, 22, 291.   | 3.8 | 21        |
| 24 | Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine. <i>Molecules</i> , 2016, 21, 889.  | 3.8 | 20        |
| 25 | Anti-Inflammatory Activities of Pentaherbs Formula, Berberine, Gallic Acid and Chlorogenic Acid in Atopic Dermatitis-Like Skin Inflammation. <i>Molecules</i> , 2016, 21, 519.  | 3.8 | 104       |
| 26 | New Potential Pharmacological Functions of Chinese Herbal Medicines via Regulation of Autophagy. <i>Molecules</i> , 2016, 21, 359.  | 3.8 | 50        |
| 27 | Aberrant Expression of Bacterial Pattern Recognition Receptor NOD2 of Basophils and Microbicidal Peptides in Atopic Dermatitis. <i>Molecules</i> , 2016, 21, 471.   | 3.8 | 13        |
| 28 | Aberrant Expression of Novel Cytokine IL-38 and Regulatory T Lymphocytes in Childhood Asthma. <i>Molecules</i> , 2016, 21, 933.   | 3.8 | 49        |
| 29 | Effect of Phyllanthus amarus Extract on 5-Fluorouracil-Induced Perturbations in Ribonucleotide and Deoxyribonucleotide Pools in HepG2 Cell Line. <i>Molecules</i> , 2016, 21, 1254.   | 3.8 | 5         |
| 30 | Natural Products from Chinese Medicines with Potential Benefits to Bone Health. <i>Molecules</i> , 2016, 21, 239.   | 3.8 | 81        |
| 31 | A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 456-467. | 4.0 | 22        |
| 32 | Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1267-1271.   | 3.3 | 8         |
| 33 | Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 1097-1108.                          | 1.9 | 14        |
| 34 | An overview of new GLP-1 receptor agonists for type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 145-158.   | 4.1 | 41        |
| 35 | Elevated Expression and Pro-Inflammatory Activity of IL-36 in Patients with Systemic Lupus Erythematosus. <i>Molecules</i> , 2015, 20, 19588-19604.   | 3.8 | 50        |
| 36 | Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 51-65.                         | 3.3 | 33        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Effects of polymorphisms in <i>ABCG2</i> , <i>SLCO1B1</i> , <i>SLC10A1</i> and <i>CYP2C9</i> / <i>19</i> on plasma concentrations of rosuvastatin and lipid response in Chinese patients. <i>Pharmacogenomics</i> , 2013, 14, 1283-1294. | 1.3 | 94        |
| 38 | Pharmacogenomics of lipid-lowering therapies. <i>Pharmacogenomics</i> , 2013, 14, 981-995.   | 1.3 | 20        |
| 39 | Preparation and Optimization of Triptolide-Loaded Solid Lipid Nanoparticles for Oral Delivery with Reduced Gastric Irritation. <i>Molecules</i> , 2013, 18, 13340-13356.   | 3.8 | 54        |
| 40 | Study of potential cardioprotective effects of <i>Ganoderma lucidum</i> (Lingzhi): results of a controlled human intervention trial. <i>British Journal of Nutrition</i> , 2012, 107, 1017-1027.   | 2.3 | 49        |
| 41 | Effects of Concomitant Therapy with Diltiazem on the Lipid Responses to Simvastatin in Chinese Subjects. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1151-1158.  | 2.0 | 8         |
| 42 | <i>Ganoderma lucidum</i> (Lingzhi™), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. <i>British Journal of Nutrition</i> , 2004, 91, 263-269.   | 2.3 | 121       |
| 43 | <i>Ganoderma lucidum</i> (Lingzhi™); acute and short-term biomarker response to supplementation. <i>International Journal of Food Sciences and Nutrition</i> , 2004, 55, 75-83.  | 2.8 | 52        |